Fibromyalgia: Memantine Reduced Pain in Small, Blinded TrialFibromyalgia: Memantine Reduced Pain in Small, Blinded Trial
Memantine, an agent primarily used to treat patients with Parkinson's or Alzheimer's disease, may provide pain relief and improve the quality of life of patients with fibromyalgia. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Forest Laboratories' Namenda Is Focus of Lawsuit
The state attorney general said Actavis’s plan to stop selling an older tablet in favor of a newer one was an attempt to maintain a monopoly. (Source: NYT Health)
Source: NYT Health - September 15, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Forest Laboratories Inc FRX NYSE Drugs (Pharmaceuticals) Suits and Litigation (Civil) Warner Chilcott Ltd WCRX NASDAQ Antitrust Laws and Competition Issues New York State Walgreen Company WAG NYSE Actavis Abbott Laboratories ABT NYSE Gen Source Type: news
Alzheimer's Drug May Enhance Stroke Recovery Alzheimer's Drug May Enhance Stroke Recovery
Memantine may improve stroke outcomes in a non-neuroprotective way, preliminary research suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Memantine Discussed in New Comprehensive Patent Search Report by Ark...
New comprehensive report “Memantine - Comprehensive patent search” elaborated by Ark Patent Intelligence is now available at MarketPublishers.com.(PRWeb July 24, 2014)Read the full story at http://www.prweb.com/releases/2014/07/prweb12045121.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 25, 2014 Category: Pharmaceuticals Source Type: news
Stroke Rounds: Dementia Drug for Stroke Recovery?
(MedPage Today) -- The Alzheimer's disease drug memantine (Namenda) might be worth a look for improving recovery from stroke, a mouse-model study suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 22, 2014 Category: Cardiology Source Type: news
Jubilant Life Sciences gets USFDA nod for generic drugs
"We expect to launch this product post patent expiry in 2015. The total market size for Namenda as per IMS is $1.85 billion per annum," the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2014 Category: Pharmaceuticals Source Type: news
Cognitive Enhancers for Mild Cognitive ImpairmentCognitive Enhancers for Mild Cognitive Impairment
What does the research say about using cholinesterase inhibitors or memantine to improve cognition or function? Medscape Psychiatry (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 8, 2014 Category: Psychiatry Tags: Psychiatry Commentary Source Type: news
Memory and mood during MDMA intoxication, with and without memantine pretreatment - de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, Heckman P, de la Torre R, Farré M, Ramaekers JG.
Previous studies have shown that single doses of MDMA can affect mood and impair memory in humans. The neuropharmacological mechanisms involved in MDMA-induced memory impairment are not clear. Memantine, an NMDA and alpha 7 nicotinic acetylcholine (ACh) re... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 4, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Memantine Discontinuation Rates Underestimated in Research?Memantine Discontinuation Rates Underestimated in Research?
Randomized clinical trials may underestimate the rate of memantine discontinuation and dose reductions in dementia patients. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's disease
US-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl to treat moderate to severe Alzheimer's t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 6, 2014 Category: Pharmaceuticals Source Type: news
Forest Files NDA For Alzheimer's Combination Therapy
Forest Laboratories announced it has submitted an NDA to the FDA for the fixed dose combination of memantine HCL extended release and donepezil HCL as treatment for moderate to severe dementia related to Alzheimer’s disease. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 5, 2014 Category: Pharmaceuticals Source Type: news
Actavis Acquires Forest Laboratories For $25 Billion
Pharmaceutical giant Actavis confirmed on Tuesday that it had purchased Forest Laboratories for $25 billion in a deal that involved cash and stock. The deal would make Actavis a global producer of both generic and brand drugs. While Actavis has long focused on generic drugs, Forest has been successful with branded products such as Lexapro and Namenda. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 21, 2014 Category: Pharmaceuticals Source Type: news
Vitamin E May Slow Functional Decline in Mild Alzheimer's Vitamin E May Slow Functional Decline in Mild Alzheimer's
A new study finds vitamin E slows functional decline and reduces caregiver burden in patients with mild Alzheimer's disease. No benefit was seen with memantine. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 2, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Could vitamin E slow dementia?
Conclusion
This was a well-conducted randomised controlled trial with a relatively long follow-up period (average two years). The aim was to see whether adding treatment with either a vitamin E supplement, memantine, or the combination, improved functional ability in people with mild to moderate Alzheimer’s disease. And who were also already receiving treatment with licensed acetylcholinesterase inhibitor drugs.
The study found a small though statistically significant difference in the decline of ability to carry out daily tasks in people taking vitamin E compared to placebo. There was also a corresponding small differ...
Source: NHS News Feed - January 2, 2014 Category: Consumer Health News Tags: Neurology Source Type: news
Vitamin E Improves Function in Mild Alzheimer's DiseaseVitamin E Improves Function in Mild Alzheimer's Disease
A new study finds vitamin E slows functional decline and reduces caregiver burden in patients with mild Alzheimer's disease. No benefit was seen with memantine. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
